Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LW402 in moderate to severe active rheumatoid arthritis
NCT06800157Phase 2Completed
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lw402 in rheumatoid arthritis (RA), sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd.. Started Feb 2023; status: completed.
02
Drugs
lw402
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06800157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06800157.